277
Participants
Start Date
January 31, 2016
Primary Completion Date
August 31, 2024
Study Completion Date
December 23, 2024
KPT-8602
Participants will receive KPT-8602 oral tablets.
ASTX727
ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
Dexamethasone
Participants will receive dexamethasone oral tablets.
Weill Cornell Medical College, New York
University of Pennsylvania Abramson Cancer Center Clinical Research Unit, Philadelphia
(USO) Virginia Cancer Specialists, Fairfax
University of Virginia, Charlottesville
Clinical Universidad de Navarra (Madrid site), Madrid
Hospital Clínic of Barcelona, Pamplona
CHU de Bordeaux, Pessac
Moffitt Cancer Center, Tampa
CHU de Tours, Tours
Vanderbilt University Medical Center, Nashville
Baptist Cancer Center, Memphis
Ohio State University, The James Cancer Hospital and Solove Research Institute, Columbus
CHU Nantes, Nantes
(USO) Oncology Hematology Care, Cincinnati
Cancer and Hematology Centers of Western Michigan, Grand Rapids
CHRU de Nancy, Vandœuvre-lès-Nancy
Sarah Cannon Cancer Center (HCA Midwest KC), Kansas City
Callahan Cancer Center, North Platte
Hôpital Cochin APHP, Paris
Hôpital Necker, Paris
(USO) Texas Oncology (Dallas), Dallas
(USO) Texas Oncology (Tyler), Tyler
MD Anderson Cancer Center, Houston
(USO) Texas Oncology Austin - Midtown, Austin
Rocky Mountain Regional VA Medical Center, Aurora
Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute), Denver
Huntsman Cancer Institute, Salt Lake City
University of New Mexico, Albuquerque
David Geffen School of Medicine at UCLA, Los Angeles
Oncology Institute of Hope and Innovation, Pasadena
University of Washington, Seattle
(USO) Compass oncology, Vancouver
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
China, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
(USO) Rocky Mountain Cancer Centers, Littleton
John Theurer Cancer Center at Hackensack UMC, Hackensack
McMaster - Juravinski Cancer Centre, Hamilton
Princess Margaret Cancer Research, Toronto
MUHC GLEN Site Cedars - Cancer Centre, Montreal
Hôpital St Louis, Paris
Hospital San Pedro de Alcántara, Cáceres
Hospital 12 de Octubre, Madrid
Hospital Universitario Central Asturias, Oviedo
Hospital La Fe, Valencia
Princess Margaret Cancer Center, Toronto
Clínica Universidad de Navarra, Barcelona
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY